- Report
- October 2025
- 199 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 196 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 181 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 181 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 189 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 182 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 184 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 183 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 191 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 194 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 190 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 199 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 193 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 181 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 185 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 195 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 181 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 189 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 197 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 198 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more